This study demonstrates that various types of STS shows positive cytoplasmic immunostaining for WT1 and STS patients should be considered candidates for WT1 peptide-based immunotherapy, particularly in cases of rhabdomyosarcoma and MPNST. The gene discussed is WT1; the disease is malignant peripheral nerve sheath tumor.